Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02760056 · ClinicalTrials.gov registry record · Phase 1
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
A Phase 1 study of Multiple Sclerosis, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02760056: Completed Phase 1 study of Multiple Sclerosis, sponsored by Oregon Health and Science University.
NCT02760056 is a Phase 1 study of Multiple Sclerosis that has completed, run by Oregon Health and Science University. The registered enrollment target is 15 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02760056, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis
Primary Outcome
MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Liothyronine sodium
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-06-06 |
| Est. Completion | 2017-01-10 |
| Phase | Phase 1 |
What the finished NCT02760056 record still lists
NCT02760056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02760056 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02760056 about?
NCT02760056 is a clinical study titled "Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study". This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis
What is the current status of trial NCT02760056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-06-06. Estimated completion is 2017-01-10.
What conditions does trial NCT02760056 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT02760056?
The interventions under investigation include: Placebo (DRUG), Liothyronine sodium (DRUG).
Who is sponsoring clinical trial NCT02760056?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02760056 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02760056's enrollment target sits among peer trials
15 284th of 315 higher than 26 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI